VRG201
Obesity
Key Facts
About Verge Genomics
Verge Genomics is a private, clinical-stage biotech leveraging a proprietary AI platform, CONVERGE®, to discover and develop novel therapeutics. The company's lead program, VRG50635, a PIKfyve inhibitor for ALS, is in Phase 1, marking a key milestone of discovering a novel target and developing a clinical candidate entirely in-house. With a pipeline spanning neuroscience, metabolic, and immunology indications, Verge aims to address diseases with complex biology and high unmet need. The company is led by a team combining drug development expertise with technology leadership.
View full company profileAbout Verge Genomics
Verge Genomics is a private, clinical-stage biotech leveraging a proprietary AI platform, CONVERGE®, to discover and develop novel therapeutics. The company's lead program, VRG50635, a PIKfyve inhibitor for ALS, is in Phase 1, marking a key milestone of discovering a novel target and developing a clinical candidate entirely in-house. With a pipeline spanning neuroscience, metabolic, and immunology indications, Verge aims to address diseases with complex biology and high unmet need. The company is led by a team combining drug development expertise with technology leadership.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |